1(2H)-PyriMidinehexanoic acid, 4-[1,1'-biphenyl]-4-yl-3,4-dihydro-6-Methyl-2-oxo-5-[(phenylMethoxy)carbonyl]-
- $159 - $633
- Product name: 1(2H)-PyriMidinehexanoic acid, 4-[1,1'-biphenyl]-4-yl-3,4-dihydro-6-Methyl-2-oxo-5-[(phenylMethoxy)carbonyl]-
- CAS: 831217-43-7
- MF: C31H32N2O5
- MW: 512.6
- EINECS:
- MDL Number:MFCD18632539
- Synonyms:4-[1,1′-Biphenyl]-4-yl-3,4-dihydro-6-methyl-2-oxo-5-[(phenylmethoxy)carbonyl]-1(2H)-pyrimidinehexanoic acid;116-9e;1(2H)-PyriMidinehexanoic acid, 4-[1,1'-biphenyl]-4-yl-3,4-dihydro-6-Methyl-2-oxo-5-[(phenylMethoxy)carbonyl]-;6-(4-([1,1'-biphenyl]-4-yl)-5-((benzyloxy)carbonyl) -6-methyl-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)hexanoic acid;116-9e >=98% (HPLC), powder;116 9e,1169e;6-(4-([1,1'-Biphenyl]-4-yl)-5-((benzyloxy)carbonyl)-6-methyl-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)hexanoic acid
2 prices
Selected condition:
Brand
- Sigma-Aldrich
Package
- 5mg
- 25mg
- ManufacturerSigma-Aldrich
- Product numberE1036
- Product description116-9e ≥98% (HPLC), powder
- Packaging5mg
- Price$159
- Updated2024-03-01
- Buy
- ManufacturerSigma-Aldrich
- Product numberE1036
- Product description116-9e ≥98% (HPLC), powder
- Packaging25mg
- Price$633
- Updated2024-03-01
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Sigma-Aldrich | E1036 | 116-9e ≥98% (HPLC), powder | 5mg | $159 | 2024-03-01 | Buy |
Sigma-Aldrich | E1036 | 116-9e ≥98% (HPLC), powder | 25mg | $633 | 2024-03-01 | Buy |
Properties
Boiling point :747.3±60.0 °C(Predicted)
Density :1.205±0.06 g/cm3(Predicted)
storage temp. :2-8°C
solubility :DMSO: >20mg/mL
form :powder
pka :4.76±0.10(Predicted)
color :white to off-white
Density :1.205±0.06 g/cm3(Predicted)
storage temp. :2-8°C
solubility :DMSO: >20mg/mL
form :powder
pka :4.76±0.10(Predicted)
color :white to off-white
Safety Information
Symbol(GHS): | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Danger | |||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||
Precautionary statements: |
|